SCHEMBL18940463

SCHEMBL18940463

COC(=O)c1ccc(OCC(=O)OC(C)(C)C)cn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.49
PSEN1 P49768 2/20 0.42
PSEN2 P49810 2/20 0.42
APH1B Q8WW43 2/20 0.42
NCSTN Q92542 2/20 0.42
APH1A Q96BI3 2/20 0.42
PSENEN Q9NZ42 2/20 0.42
PTPN1 P18031 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.40
KDM4E B2RXH2 2/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
GPR119 Q8TDV5 1/20 0.39
GAA P10253 1/20 0.39
DYRK1A Q13627 1/20 0.39
PARP1 P09874 1/20 0.38
ATR Q13535 1/20 0.38
P4HTM Q9NXG6 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20593092 0.86 P4HTM (0.52) MAPK1PSEN1PSEN2APH1BNCSTN
SCHEMBL8593499 0.86 PTPN1 (0.43) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL31286721 0.83 MAPK1 (0.43) MAPK1
SCHEMBL22371614 0.82 MAPK1 (0.43) MAPK1L3MBTL1KDM4ERAB9AGPR119
SCHEMBL21200606 0.82 LCK (0.44) MAPK1PSEN1PSEN2APH1BNCSTN
SCHEMBL8555283 0.82 PTPN1 (0.41) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL25247080 0.82 GAA (0.51) MAPK1KDM4EGAAALDH1A1
SCHEMBL30404318 0.82 GAA (0.51) MAPK1KDM4EGAAALDH1A1
SCHEMBL23397123 0.81 P4HTM (0.52) PTPN1L3MBTL1KDM4EMEN1KMT2A
SCHEMBL18940415 0.81 MAPK1 (0.56) MAPK1L3MBTL1KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11661397-B2 1,4-disubstituted imidazole derivative Sumitomo Pharma Co., Ltd. (JP) 2023-05-30 US disclosed
US-11661397-B2 1,4-disubstituted imidazole derivative Sumitomo Pharma Co., Ltd. (JP) 2023-05-30 US disclosed
US-11661397-B2 1,4-disubstituted imidazole derivative Sumitomo Pharma Co., Ltd. (JP) 2023-05-30 US disclosed
US-11434472-B2 Agent for removing undifferentiated iPS cells Sumitomo Pharma Co., Ltd. (JP) 2022-09-06 US disclosed
US-11434472-B2 Agent for removing undifferentiated iPS cells Sumitomo Pharma Co., Ltd. (JP) 2022-09-06 US disclosed
US-20210171440-A1 1,4-DISUBSTITUTED IMIDAZOLE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2021-06-10 US disclosed
US-20210171440-A1 1,4-DISUBSTITUTED IMIDAZOLE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2021-06-10 US disclosed
CN-107922386-B 1, 4-disubstituted imidazole derivatives 大日本住友制药株式会社 2021-04-02 CN disclosed
US-10807945-B2 1,4-disubstituted imidazole derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2020-10-20 US disclosed
US-10807945-B2 1,4-disubstituted imidazole derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2020-10-20 US disclosed
EP-3560494-A1 DRUG TARGETING CANCER STEM CELL Sumitomo Dainippon Pharma Co., Ltd. (JP) 2019-10-30 EP disclosed
WO-2018117196-A1 DRUG TARGETING CANCER STEM CELL 大日本住友製薬株式会社 2018-06-28 WO disclosed
EP-3312170-A1 1,4-DI-SUBSTITUTED IMIDAZOLE DERIVATIVE Sumitomo Dainippon Pharma Co., Ltd. (JP) 2018-04-25 EP disclosed
US-9828362-B2 1,4-disubstituted imidazole derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2017-11-28 US disclosed
US-9828362-B2 1,4-disubstituted imidazole derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2017-11-28 US disclosed
US-9828362-B2 1,4-disubstituted imidazole derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2017-11-28 US disclosed
WO-2017146128-A1 IMIDAZOLYLAMIDE DERIVATIVE 大日本住友製薬株式会社 2017-08-31 WO disclosed
US-20170166552-A1 1,4-DISUBSTITUTED IMIDAZOLE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2017-06-15 US disclosed
US-20170166552-A1 1,4-DISUBSTITUTED IMIDAZOLE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2017-06-15 US disclosed
US-20170166552-A1 1,4-DISUBSTITUTED IMIDAZOLE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2017-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170166552-A1 1,4-DISUBSTITUTED IMIDAZOLE DERIVATIVE NR4A3, NR0B1, NR2C2 MAPK1 2980/4885PSEN1 4005/4885PSEN2 4022/4885
US-11434472-B2 Agent for removing undifferentiated iPS cells SALL4, NR4A2, NES MAPK1 2722/4885PSEN1 2071/4885PSEN2 2477/4885
US-20210171440-A1 1,4-DISUBSTITUTED IMIDAZOLE DERIVATIVE NR4A3, NR0B1, NR2C2 MAPK1 2980/4885PSEN1 4005/4885PSEN2 4022/4885
US-11661397-B2 1,4-disubstituted imidazole derivative NR4A3, NR0B1, NR2C2 MAPK1 2980/4885PSEN1 4005/4885PSEN2 4022/4885
US-10807945-B2 1,4-disubstituted imidazole derivative NR0B1, NR4A3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 MAPK1 3007/4885PSEN1 3739/4885PSEN2 3854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.